PRMT inhibitor promotes SMN2 exon 7 inclusion and synergizes with nusinersen to rescue SMA mice
EMBO Molecular Medicine · 2023
DOI: 10.15252/emmm.202317683 ↗Kurz gefasst
Fachartikel in der Zeitschrift EMBO Molecular Medicine, 2023. Verfasst von Anna J Kordala und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology Anatomy and Genetics, University of Oxford, Oxford, UK. Hauptthemen laut MEDLINE: Muscular Atrophy, Spinal, Quality of Life. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 125 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Medical Research Council, UKRI ¦ MRC ¦ Medical Research Foundation.
Abstract (Originalsprache)
Spinal muscular atrophy (SMA) is a leading genetic cause of infant mortality. The advent of approved treatments for this devastating condition has significantly changed SMA patients' life expectancy and quality of life. Nevertheless, these are not without limitations, and research efforts are underway to develop new approaches for improved and long‐lasting benefits for patients. Protein arginine methyltransferases (PRMTs) are emerging as druggable epigenetic targets, with several small‐molecule PRMT inhibitors already in clinical trials. From a screen of epigenetic molecules, we have identified MS023, a potent and selective type I PRMT inhibitor able to promote SMN2 exon 7 inclusion in preclinical SMA models. Treatment of SMA mice with MS023 results in amelioration of the disease phenotype, with strong synergistic amplification of the positive effect when delivered in combination with the antisense oligonucleotide nusinersen. Moreover, transcriptomic analysis revealed that MS023 treatment has minimal off‐target effects, and the added benefit is mainly due to targeting neuroinflammation. Our study warrants further clinical investigation of PRMT inhibition both as a stand‐alone and add‐on therapy for SMA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology Anatomy and Genetics, University of Oxford, Oxford, UK.
- Department of Paediatrics, University of Oxford, Oxford, UK.
- Institute of Developmental and Regenerative Medicine (IDRM), Oxford, UK.
- Centre for Discovery Brain Sciences, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
- Euan McDonald Centre for Motor Neuron Disease Research, University of Edinburgh, Edinburgh, UK.
- Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK.
ORCID-Profile: Jessica Stoodley, Nina Ahlskog, Antonio Garcia Guerra, Kevin Talbot, Carlo Rinaldi
Förderung
- Wellcome Trust
- Medical Research Council
- UKRI ¦ MRC ¦ Medical Research Foundation
Zitieren
APA
Kordala, A. J., Stoodley, J., Ahlskog, N., Hanifi, M., Garcia Guerra, A., Bhomra, A., Lim, W. F., Murray, L. M., Talbot, K., Hammond, S. M., Wood, M. J., & Rinaldi, C. (2023). PRMT inhibitor promotes SMN2 exon 7 inclusion and synergizes with nusinersen to rescue SMA mice. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.202317683
Vancouver
Kordala AJ, Stoodley J, Ahlskog N, Hanifi M, Garcia Guerra A, Bhomra A, et al. PRMT inhibitor promotes SMN2 exon 7 inclusion and synergizes with nusinersen to rescue SMA mice. EMBO Molecular Medicine. 2023. doi:10.15252/emmm.202317683
BibTeX
@article{Kordala2023,
author = {Kordala, Anna J and Stoodley, Jessica and Ahlskog, Nina and Hanifi, Muhammad and Garcia Guerra, Antonio and Bhomra, Amarjit and Lim, Wooi Fang and Murray, Lyndsay M and Talbot, Kevin and Hammond, Suzan M and Wood, Matthew Ja and Rinaldi, Carlo},
title = {PRMT inhibitor promotes SMN2 exon 7 inclusion and synergizes with nusinersen to rescue SMA mice},
journal = {EMBO Molecular Medicine},
year = {2023},
doi = {10.15252/emmm.202317683}
}
EUVIMED